Japan Approves World’s First Self-Amplifying mRNA COVID Vaccine
Implications for Canada?
Japan has recently approved ARCT-154, the world’s first self-amplifying mRNA COVID-19 vaccine, for older adults and those with severe health conditions. As Canada continues to navigate its vaccination strategy, this development raises important questions about safety and efficacy.
Zero long-term safety data.
While Japanese officials cite promising clinical trial results from Arcturus Therapeutics, experts have expressed significant concerns. The technology, which allows the vaccine to replicate within the body, lacks long-term safety data, prompting warnings about potential risks, including adverse health effects and links to cancer.
As Canada monitors global vaccine developments, the emergence of self-amplifying mRNA technology may influence its approach to future vaccinations. Experts advocate for thorough testing and independent research to ensure public safety, emphasizing the need for caution as new vaccines are introduced.
With the backdrop of an evolving pandemic landscape, Canada must remain vigilant and prioritize transparent evaluation of any new vaccine technologies before widespread implementation.
Read more: Japan Approves World’s First ‘Self-amplifying’ mRNA COVID Shot — Is the U.S. Next?
********************************************************************************************************************